Sudan Journal of Medical Sciences

Published date: Sep 30 2024

Journal Title: Sudan Journal of Medical Sciences

Issue title: Sudan JMS: Volume 19 (2024), Issue No. 3

Pages: 378 - 388

DOI: 10.18502/sjms.v19i3.14509

Shumaila SarwarInstitute of Pharmaceutical Sciences, University of Veterinary & Animal Sciences, Lahore, Pakistan

Amal K Sulimanalbarqok@yahoo.comDepartment of Pharmacy Practice, College of Clinical Pharmacy, King Faisal University, Al-Ahsa, Saudi Arabia

Allah Bukhshabukhsh@uvas.edu.pkInstitute of Pharmaceutical Sciences, University of Veterinary & Animal Sciences, Lahore, Pakistan

Tahir Mehmood Khantahir.khan@uvas.edu.pkInstitute of Pharmaceutical Sciences, University of Veterinary & Animal Sciences, Lahore, Pakistan

Mirza Rafi BaigDr.Mirzabaig@dpc.eduDepartment of Clinical Pharmacy & Pharmacotherapeutics, Dubai Pharmacy College for Girls, Dubai, United Arab Emirates

Sobia NaureenConsultant Gynecologist, Govt Said Mitha Teaching Hospital, Lahore

Background: This study observes fetal, pregnancy, and maternal outcomes with different regimens of Magnesium sulphate (MgSO4), used for prophylaxis and treatment of convulsions in eclampsia.
Methods: In this observational study, the current prescribing practice and management outcomes of pre-eclampsia/eclampsia were observed in three tertiary care hospitals in Lahore, Pakistan. Data were collected by using data collection form, containing information related to patient demographics, history, laboratory findings, drug administration record, and therapeutic outcomes for pregnancy, fetus, and mother.
Results: Of the 50 patients studied, most (74%) were of eclampsia. The mean age of the patients was 25.7 (+5.05) years with the majority (36%) in the age range 21–25 years. Forty-one patients received MgSO4, of which most received the Pritchard regimen (n = 35), whereas only 5 patients were managed with Zuspan regimen. Liner logistic analysis revealed better fetal outcomes (OR 0.217, CI –0.283 – 1.543) and pregnancy outcomes (OR 0.186, CI –0.164 – 0.635) with Zuspan regimen as compared to Pritchard. Whereas, both regimens showed no difference in maternal outcomes (OR 0.044, CI –0.129 – 0.170).
Conclusion: Zuspan regimen proved to be better in morbidity and mortality associated with eclampsia. Additionally, national as well as institutional guidelines should be developed, implemented, properly monitored, and evaluated for management of preeclampsia/ eclampsia. Mandatory in-service training and expertise should be provided for health professionals at all levels of the healthcare system, especially those working in gynecological setup.

Keywords: pre-eclampsia, magnesium sulphate, eclampsia, prescribing practices, management outcomes, Pakistan

[1] August, P., & Sibai, B. M. (2024). Preeclampsia: Clinical features and diagnosis. UpToDate.

[2] Duley, L. (2005). Evidence and practice: The magnesium sulphate story. Best Practice & Research. Clinical Obstetrics & Gynaecology, 19(1), 57–74. https://doi.org/10.1016/j.bpobgyn.2004.10.010

[3] Murlidhar, V., & Bolia, S. (2006). Intensive care management of severe pre-eclampsia and eclampsia. Apollo Medicine, 3(1), 102–110. https://doi.org/10.1177/0976001620060115

[4] Bilano, V. L., Ota, E., Ganchimeg, T., Mori, R., & Souza, J. P. (2014). Risk factors of preeclampsia/ eclampsia and its adverse outcomes in low- and middle-income countries: A WHO secondary analysis. PLoS One, 9(3), e91198. https://doi.org/10.1371/journal.pone.0091198

[5] Khan, K. S., Wojdyla, D., Say, L., Gülmezoglu, A. M., & Van Look, P. F. (2006). WHO analysis of causes of maternal death: A systematic review. Lancet, 367(9516), 1066–1074. https://doi.org/10.1016/S0140- 6736(06)68397-9

[6] Steegers, E. A., von Dadelszen, P., Duvekot, J. J., & Pijnenborg, R. (2010). Pre-eclampsia. Lancet, 376(9741), 631–644. https://doi.org/10.1016/S0140- 6736(10)60279-6

[7] Sibai, B., Dekker, G., & Kupferminc, M. (2005). Preeclampsia. Lancet, 365(9461), 785–799. https://doi. org/10.1016/S0140-6736(05)17987-2

[8] Rathore, R., Butt, N. F., Iqbal, A., & Khan, M. Z. U. (2010). Complications and outcome of patients of pre-eclampsia and eclampsia presenting to medical wards of Mayo Hospital Lahore. Annals of King Edward Medical University, 16(1), 17.

[9] National Collaborating Centre for Women’s and Children’s Health (UK). (2010). Hypertension in pregnancy: The management of hypertensive disorders during pregnancy. London: RCOG Press.

[10] WHO. (2011). WHO recommendations for prevention and treatment of pre-eclampsia and eclampsia: Summary of recommendations. https://iris.who.int/bitstream/handle/10665/119627/ WHO_RHR_14.17_eng.pdf

[11] Magee, L. A., Miremadi, S., Li, J., Cheng, C., Ensom, M. H., Carleton, B., Côté, A. M., & von Dadelszen, P. (2005). Therapy with both magnesium sulfate and nifedipine does not increase the risk of serious magnesium-related maternal side effects in women with preeclampsia. American Journal of Obstetrics and Gynecology, 193(1), 153–163. https://doi.org/10.1016/j.ajog.2004.11.059

[12] Belfort, M. A., Anthony, J., Saade, G. R., Allen, J. C., Jr., & the Nimodipine Study Group. (2003). A comparison of magnesium sulfate and nimodipine for the prevention of eclampsia. The New England Journal of Medicine, 348(4), 304–311. https://doi.org/ 10.1056/NEJMoa021180

[13] Euser, A. G., & Cipolla, M. J. (2009). Magnesium sulfate for the treatment of eclampsia: A brief review. Stroke, 40(4), 1169–1175. https://doi.org/10. 1161/STROKEAHA.108.527788

[14] Tukur, J. (2009). The use of magnesium sulphate for the treatment of severe pre-eclampsia and eclampsia. Annals of African Medicine, 8(2), 76–80. https://doi.org/10.4103/1596-3519.56232

[15] Zuspan, F. P. (1978). Problems encountered in the treatment of pregnancy-induced hypertension. A point of view. American Journal of Obstetrics and Gynecology, 131(6), 591–597. https://doi.org/10.1016/0002-9378(78)90816-5

[16] Pritchard, J. A., Cunningham, F. G., & Pritchard, S. A. (1984). The Parkland Memorial Hospital protocol for treatment of eclampsia: Evaluation of 245 cases. American Journal of Obstetrics and Gynecology, 148(7), 951–963. https://doi.org/10.1016/ 0002-9378(84)90538-6

[17] Begum, R., Begum, A., Johanson, R., Ali, M. N., & Akhter, S. (2001). A low dose (“Dhaka”) magnesium sulphate regime for eclampsia. Acta Obstetricia et Gynecologica Scandinavica, 80(11), 998–1002. https://doi.org/10.1034/j.1600-0412.2001.801105.x

[18] Uzan, J., Carbonnel, M., Piconne, O., Asmar, R., & Ayoubi, J. M. (2011). Pre-eclampsia: Pathophysiology, diagnosis, and management. Vascular Health and Risk Management, 7(7), 467–474.

[19] Malhan, A., Hyder, M.., Baloch, S., Zahegul, Roshan, S., Dembra, G., & Arshad, M. (2023). Frequency of preeclampsia in pregnant women presenting in a tertiary hospital: Frequency of preeclampsia in pregnant women. Pakistan Journal of Health Sciences, 4(04), 30–33. https://doi.org/10.54393/pjhs.v4i04.652

[20] Soomro, S., Kumar, R., Lakhan, H., & Shaukat, F. (2019). Risk factors for pre-eclampsia and eclampsia disorders in tertiary care center in Sukkur, Pakistan. Cureus, 11(11), e6115. https://doi.org/10.7759/cureus.6115

[21] Dekker, G., & Sibai, B. (2001). Primary, secondary, and tertiary prevention of pre-eclampsia. Lancet, 357(9251), 209–215. https://doi.org/10.1016/S0140- 6736(00)03599-6

[22] Thangaratinam, S., Langenveld, J., Mol, B. W., & Khan, K. S. (2011). Prediction and primary prevention of pre-eclampsia. Best Practice & Research. Clinical Obstetrics & Gynaecology, 25(4), 419–433. https://doi.org/10.1016/j.bpobgyn.2011.02.008

[23] Drug Regulatory Authority of Pakistan. (2022). National essential medicine lists.

[24] Shoaib, T., Khan, S., Javed, I., & Bhutta, S. Z. (2009). Loading dose of magnesium sulphate versus standard regime for prophylaxis of pre-eclampsia. Journal of the College of Physicians and Surgeons— Pakistan, 19(1), 30–33.

[25] McDonald, S. D., Lutsiv, O., Dzaja, N., & Duley, L. (2012). A systematic review of maternal and infant outcomes following magnesium sulfate for preeclampsia/ eclampsia in real-world use. International Journal of Gynaecology and Obstetrics, 118(2), 90– 96. https://doi.org/10.1016/j.ijgo.2012.01.028

[26] Duley, L., Henderson-Smart, D. J., Walker, G. J., & Chou, D. (2010). Magnesium sulphate versus diazepam for eclampsia. Cochrane Database of Systematic Reviews, 2010, CD000127.

[27] Shaheen, B., Hassan, L., & Obaid, M. (2003). Eclampsia, a major cause of maternal and perinatal mortality: A prospective analysis at a tertiary care hospital of Peshawar. JPMA. The Journal of the Pakistan Medical Association, 53(8), 346–350.

[28] Sheikh, S., Qureshi, R. N., Khowaja, A. R., Salam, R., Vidler, M., Sawchuck, D., von Dadelszen, P., Zaidi, S., Bhutta, Z., & the CLIP Working Group. (2016). Health care provider knowledge and routine management of pre-eclampsia in Pakistan. Reproductive Health, 13(2, Suppl 2), 104. https://doi.org/10.1186/s12978- 016-0215-z

[29] White Ribbon Alliance-Pakistan. (2020). Saving mother’s life: addressing barriers to the use of magnesium sulphate is a project funded by the Maternal and Newborn Health Programme - Research and Advocacy Fund (RAF), and implemented by White Ribbon Alliance-Pakistan. https://fsm.org.pk/wpcontent/ uploads/2020/08/Policy-Brief-MGSO4.pdf

[30] National Institute of Population Studies, Islamabad, Pakistan. (2008). Pakistan demographic and health survey 2006-07. https://dhsprogram.com/pubs/pdf/ FR200/FR200.pdf

[31] Shaikh, B. T., & Hatcher, J. (2005). Health seeking behaviour and health service utilization in Pakistan: Challenging the policy makers. Journal of Public Health, 27(1), 49–54. https://doi.org/10.1093/ pubmed/fdh207

[32] Anwar, M., Green, J., & Norris, P. (2012). Healthseeking behaviour in Pakistan: A narrative review of the existing literature. Public health, 126(6), 507–517.